A Phase III Study to Evaluate the Safety and Efficacy of Ganciclovir (Dihydroxypropoxymethyl Guanine [DHPG]) Treatment of Symptomatic Central Nervous System (CNS) Congenital Cytomegalovirus (CMV) Infections.

NCT00001100 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

130

Enrollment

NIH

Sponsor class

Conditions

Cytomegalovirus Infections

Interventions

DRUG: ganciclovir

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)